Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc (HXBM) - Total Liabilities
Latest total liabilities as of December 2013: $202.00K USD
Based on the latest financial reports, Helix BioMedix Inc (HXBM) has total liabilities worth $202.00K USD as of December 2013.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Helix BioMedix Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Helix BioMedix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Helix BioMedix Inc Competitors by Total Liabilities
The table below lists competitors of Helix BioMedix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jse Ltd
BE:JF6
|
Germany | €55.40 Billion |
|
Federal Screw Works
PINK:FSCR
|
USA | $34.68 Million |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
UK | GBX40.60 Million |
|
SHENZHOU INTL GROUP
BE:S6L
|
Germany | €15.74 Billion |
|
Edgio Inc
NASDAQ:EGIO
|
USA | $299.67 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Helix BioMedix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Helix BioMedix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Helix BioMedix Inc (2000–2024)
The table below shows the annual total liabilities of Helix BioMedix Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $127.78K | +90.92% |
| 2023-12-31 | $66.93K | -46.98% |
| 2022-12-31 | $126.24K | +17.34% |
| 2021-12-31 | $107.59K | -96.84% |
| 2020-12-31 | $3.40 Million | +1583.50% |
| 2013-12-31 | $202.00K | -80.16% |
| 2012-12-31 | $1.02 Million | +131.73% |
| 2011-12-31 | $439.30K | +24.08% |
| 2010-12-31 | $354.04K | -95.07% |
| 2009-12-31 | $7.18 Million | +62.55% |
| 2008-12-31 | $4.42 Million | +1157.47% |
| 2007-12-31 | $351.36K | +37.33% |
| 2006-12-31 | $255.86K | +14.22% |
| 2005-12-31 | $224.00K | +19.15% |
| 2004-12-31 | $188.00K | -8.74% |
| 2003-12-31 | $206.00K | -44.62% |
| 2002-12-31 | $372.00K | -82.08% |
| 2001-12-31 | $2.08 Million | +321.95% |
| 2000-12-31 | $492.00K | -- |